Premium
Do we have enough evidence for recommending therapeutic apheresis for natalizumab‐related progressive multifocal leukoencephalopathy patients? Comment on “Guidelines on the use of therapeutic apheresis in clinical practice‐evidence‐based approach from the Writing Committee of the American Society for apheresis: The seventh special issue.”
Author(s) -
Landi Doriana,
Centonze Diego,
Marfia Girolama Alessandra,
Capra Ruggero,
Scarpazza Cristina
Publication year - 2018
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.21616
Subject(s) - medicine , natalizumab , progressive multifocal leukoencephalopathy , apheresis , clinical practice , multiple sclerosis , family medicine , platelet , psychiatry